Current state of knowledge on oral anticoagulant reversal using procoagulant factors;Estado actual del conocimiento sobre el uso de factores procoagulantes para revertir el efecto de anticoagulantes orales

Annals of Pharmacotherapy

Volumn 47, Issue 6, 2013, Pages 841-855

  Nitzki George, Diane ^a   Wozniak, Izabela ^a   Caprini, Joseph A ^b  

^a NORTHSHORE UNIVERSITY HEALTHSYSTEM   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED PROTHROMBIN COMPLEX; ANTICOAGULANT AGENT; APIXABAN; BLOOD CLOTTING FACTOR 9 COMPLEX; DABIGATRAN ETEXILATE; ENOXAPARIN; FATTY ACID BINDING PROTEIN; FRESH FROZEN PLASMA; PROCOAGULANT; PROTEIN C; PROTEIN S; PROTHROMBIN COMPLEX; RECOMBINANT BLOOD CLOTTING FACTOR 7A; RIVAROXABAN; VITAMIN K GROUP; WARFARIN;

ARTICLE; BLEEDING; CEREBROVASCULAR ACCIDENT; CRYOPRECIPITATE; DATA BASE; DEEP VEIN THROMBOSIS; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG EFFICACY; DRUG SAFETY; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HEART VENTRICLE FIBRILLATION; HUMAN; INTERNATIONAL NORMALIZED RATIO; LUNG EMBOLISM; MEDLINE; PRIORITY JOURNAL; PROTHROMBIN TIME; SIDE EFFECT; THORAX PAIN; THROMBOSIS; VENOUS THROMBOEMBOLISM;

ADMINISTRATION, ORAL; ANIMALS; ANTICOAGULANTS; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HEMORRHAGE; HUMANS;

EID: 84878508201     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1R724     Document Type: Article

References (106)

1. Crowther MA, Warkentin TE. Bleeding risk and the management of bleeding complications in patients undergoing anticoagulant therapy: focus on new anticoagulant agents. Blood 2008;111:4871-4879.
2. Product information. Pradaxa (dabigatran etexilate mesylate). Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc., April 2013.
3. Product information. Xarelto (rivaroxaban). Titusville, New Jersey: Janssen Pharmaceuticals, Inc., March 2013.
4. Product information. Eliquis (apixaban). Princeton, New Jersey: Bristol-Myers Squibb Company, December 2012.
5. Hirsh J, Dalen J, Anderson DR, et al. Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest 2001; 119:8S-21S.
6. Schulman S, Crowther MA. How I treat with anticoagulants in 2012: new and old anticoagulants, and when and how to switch. Blood 2012; 119:3016-3023.
7. Eriksson BI, Dahl OE, Rosencher N, et al. Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. J Thromb Haemost 2007;5:2178-2185.
8. Eriksson BI, Dahl OE, Rosencher N, et al. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet 2007;370:949-956.
9. Eriksson BI, Dahl OE, Huo MH, et al. Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II*). A randomised, double-blind, non-inferiority trial. Thromb Haemost 2011;105:721-729.
10. RE-MOBILIZE Writing Committee; Ginsberg JS, Davidson BL, et al. Oral thrombin inhibitor dabigatran etexilate vs North American enoxa-parin regimen for prevention of venous thromboembolism after knee arthroplasty surgery. J Arthroplasty 2009;24:1-9.
11. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009;361:1139-1151.
12. Schulman S, Kearon C, Kakkar AK, et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 2009; 361:2342-2352.
13. Eriksson BI, Borris LC, Friedman RJ, et al. Rivaroxaban versus enoxa-parin for thromboprophylaxis after hip arthroplasty. N Engl J Med 2008;358:2765-2775.
14. Kakkar AK, Brenner B, Dahl OE, et al. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboem-bolism after total hip arthroplasty: a double-blind, randomised controlled trial. Lancet 2008;372:31-39.
15. Lassen MR, Ageno W, Borris LC, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med 2008;358:2776-2786.
16. Turpie AG, Lassen MR, Davidson BL, et al. Rivaroxaban versus enoxa-parin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial. Lancet 2009;373:1673-1680.
17. EINSTEIN Investigators; Bauersachs R, Berkowitz SD, et al. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010;363:2499-2510.
18. Romualdi E, Donadini MP, Ageno W. Oral rivaroxaban after symptomatic venous thromboembolism: the continued treatment study (EINSTEIN-extension study). Expert Rev Cardiovasc Ther 2011;9:841-844.
19. Lassen MR, Raskob GE, Gallus A, Pineo G, Chen D, Portman RJ. Apix-aban or enoxaparin for thromboprophylaxis after knee replacement. N Engl J Med 2009;361:594-604.
20. Lassen MR, Gallus A, Raskob GE, et al. Apixaban versus enoxaparin for thromboprophylaxis after hip replacement. N Engl J Med 2010;363: 2487-2498.
21. Harper P, Young L, Merriman E. Bleeding risk with dabigatran in the frail elderly. N Engl J Med 2012;366:864-866.
22. Lillo-Le Louët A, Wolf M, Soufir L, et al. Life-threatening bleeding in four patients with an unusual excessive response to dabigatran: implications for emergency surgery and resuscitation. Thromb Haemost 2012; 108:583-585.
23. Regulation THS. Dabigatran (Pradaxa): risk of bleeding relating to use. Australia: TGA Health Safety Regulation. http://www.tga.gov.au/safety/alerts-medicine-dabigatran-111005.htm (accessed 2012 Oct 30).
24. Favaloro EJ, Lippi G, Koutts J. Laboratory testing of anticoagulants: the present and the future. Pathology 2011;43:682-692.
25. Johansson PI. Coagulation monitoring of the bleeding traumatized patient. Curr Opin Anaesthesiol 2012;25:235-241.
26. Casutt M, Konrad C, Schuepfer G. Effect of rivaroxaban on blood coagulation using the viscoelastic coagulation test ROTEM. Anaesthesist 2012;61:948-953.
27. Ammollo CT, Semeraro F, Incampo F, Semeraro N, Colucci M. Dabiga-tran enhances clot susceptibility to fibrinolysis by mechanisms dependent on and independent of thrombin-activatable fibrinolysis inhibitor. J Thromb Haemost 2010;8:790-798.
28. van Ryn J, Schurer J, Kink-Eiband M, Clemens A. The successful reversal of dabigatran-induced bleeding by coagulation factor concentrates in a rat tail bleeding model do not correlate with ex vivo markers of antico-agulation. Presented at: 53rd ASH Annual Meeting and Exposition, San Diego, CA, December 11, 2011.
29. Favaloro EJ, Bonar R, Aboud M, et al.; RCPA QAP in Haematology. How useful is the monitoring of (low molecular weight) heparin therapy by anti-Xa assay? The laboratory perspective. Lab Hematol 2005;11: 157-162.
30. Favaloro EJ, Bonar R, Sioufi J, et al. on behalf of the RCPA QAP in Haematology. An international survey of current practice in the laboratory assessment of anticoagulant therapy with heparin. Pathology 2005;37: 234-238.
31. Mani H, Hesse C, Stratmann G, Lindhoff-Last E. Ex vivo effects of low-dose rivaroxaban on specific coagulation assays and coagulation factor activities in patients under real life conditions. Thromb Haemost 2013; 109:127-136.
32. Miyares MA, Davis K. Newer oral anticoagulants: a review of laboratory monitoring options and reversal agents in the hemorrhagic patient. Am J Health Syst Pharm 2012;69:e28-39.
33. Benjamin RJ, McLaughlin LS. Plasma components: properties, differences, and uses. Transfusion.2012;52(suppl 1):9S-19S.
34. Rodgers GM. Prothrombin complex concentrates in emergency bleeding disorders. Am J Hematol 2012;87:898-902.
35. Franchini M, Lippi G. Prothrombin complex concentrates: an update. Blood Transfus 2010;8:149-154.
36. Sørensen B, Spahn DR, Innerhofer P, Spannagl M, Rossaint R. Clinical review: -prothrombin complex concentrates-evaluation of safety and throm-bogenicity. Crit Care 2011;15:201-210. Erratum: Crit Care 2011;15:409.
37. Samama CM. Prothrombin complex concentrates: a brief review. Eur J Anaesthesiol 2008;25:784-789.
38. Product information. Bebulin VH (factor IX Complex). Westlake Village, CA: Baxter Healthcare Corporation, April 2011.
39. Product information. Profilnine SD (factor IX Complex). Los Angeles, CA: Grifols Biologicals Inc., April 2010.
40. Product information. FEIBA NF (anti-inhibitor coagulant complex). Westlake Village, CA: Baxter Healthcare Corporation, February 2011.
41. Product information. Beriplex P/N (human prothrombin complex). Ottawa, Canada: CSL Behring Canada Inc., November 2010.
42. Product information. Octaplex (human prothrombin complex). Scarborough, Canada: Octapharma Canada, Inc., April 28, 2010.
43. Product information. Cofact (human prothrombin complex). Amsterdam, Netherlands: Sanquin, December 25, 2011.
44. Product information. Kanokad (human prothrombin complex). Courtabœuf, Cedex, France: LFB-Biomedicaments, February 18, 2009.
45. Kalina U, Bickhard H, Schulte S. Biochemical comparison of seven commercially available prothrombin complex concentrates. Int J Clin Pract 2008;62:1614-1622.
46. Rolfe S, Papadopoulos S, Cabral KP. Controversies of anticoagulation reversal in life-threatening bleeds. J Pharm Pract 2010;23:217-225.
47. Preston FE, Laidlaw ST, Sampson B, Kitchen S. Rapid reversal of oral anti-coagulation with warfarin by a prothrombin complex concentrate (Beriplex): efficacy and safety in 42 patients. Br J Haematol 2002;116:619-624.
48. van Aart L, Eijkhout HW, Kamphuis JS, et al. Individualized dosing regimen for prothrombin complex concentrate more effective than standard treatment in the reversal of oral anticoagulant therapy: an open, prospective randomized controlled trial. Thromb Res 2006;118:313-320.
49. Bershad EM, Suarez JI. Prothrombin complex concentrates for oral anticoagulant therapy-related intracranial hemorrhage: a review of the literature. Neurocrit Care 2010;12:403-413.
50. Fredriksson K, Norrving B, Stromblad LG. Emergency reversal of anti-coagulation after intracerebral hemorrhage. Stroke 1992;23:972-977.
51. Makris M, Greaves M, Phillips WS, Kitchen S, Rosendaal FR, Preston FE. Emergency oral anticoagulant reversal: the relative efficacy of infusions of fresh frozen plasma and clotting factor concentrate on correction of the coagulopathy. Thromb Haemost 1997;77:477-480.
52. Boulis NM, Bobek MP, Schmaier A, Hoff JT. Use of factor IX complex in warfarin-related intracranial hemorrhage. Neurosurgery 1999;45:1113-1118.
53. Cartmill M, Dolan G, Byrne JL, Byrne PO. Prothrombin complex concentrate for oral anticoagulant reversal in neurosurgical emergencies. Br J Neurosurg 2000;14:458-461.
54. Siddiq F, Jalil A, McDaniel C, et al. Effectiveness of Factor IX complex concentrate in reversing warfarin associated coagulopathy for intracere-bral hemorrhage. Neurocrit Care 2008;8:36-41.
55. Demeyere R, Gillardin S, Arnout J, Strengers PF. Comparison of fresh frozen plasma and prothrombin complex concentrate for the reversal of oral anticoagulants in patients undergoing cardiopulmonary bypass surgery: a randomized study. Vox Sang 2010;99:251-260.
56. Lemon SJ Jr, Crannage AJ. Pharmacologic anticoagulation reversal in the emergency department. Adv Emer Nurs J 2011;33:212-223.
57. Vigue B. Bench-to-bedside review: optimising emergency reversal of vitamin K antagonists in severe haemorrhage-from theory to practice. Crit Care 2009;13:209-219.
58. Canadian Blood Services. Availability of Beriplex P/N (human pro-thrombin complex) Customer letter 2011-20. Ottawa, Canada: Canadian Blood Services, 2011.
59. Simon CD, Perkins J, Barras P, Eastridge B, Blackbourne LH. Fresh frozen plasma. US Army Med Dep J 2009:64-67.
60. Medscape. Fresh frozen plasma (blood component). http://reference.medscape.com/drug/ffp-fresh-frozen-plasma-999499 (accessed 2012 Oct 30).
61. Product information. NovoSeven RT (coagulation factor VIIa recombi-nant). Bagsvaerd, Denmark: Novo Nordisk, December 2012.
62. Wójcik C, Schymik ML, Cure EG. Activated prothrombin complex concentrate factor VIII inhibitor bypassing activity (FEIBA) for the reversal of warfarin-induced coagulopathy. Int J Emerg Med 2009;2:217-225.
63. Gernsheimer T. Puget Sound Blood Center. Blood component therapy 2010. http://www.psbc.org/therapy/ffp.htm (accessed 2012 Oct 30).
64. Goodnough LT, Shander A. How I treat warfarin-associated coagulopa-thy in patients with intracerebral hemorrhage. Blood 2011;117:6091-6099.
65. Wiedermann CJ, Stockner I. Warfarin-induced bleeding complications- clinical presentation and therapeutic options. Thromb Res 2008;122(suppl 2):S13-S18.
66. Ageno W, Gallus AS, Wittkowsky A, Crowther M, Hylek EM, Palareti G; American College of Chest Physicians. Oral anticoagulant therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2012;141:e44S-88S.
67. Broderick J, Connolly S, Feldmann E, et al. Guidelines for the management of spontaneous intracerebral hemorrhage in adults: 2007 update: a guideline from the American Heart Association/American Stroke Association Stroke Council, High Blood Pressure Research Council, and the Quality of Care and Outcomes in Research Interdisciplinary Working Group. Stroke 2007;38:2001-2023.
68. Elliott J, Smith M. The acute management of intracerebral hemorrhage: a clinical review. Anesth Analg 2010;110:1419-1427.
69. Hanley JP. Warfarin reversal. J Clin Pathol 2004;57:1132-1139.
70. Pabinger I, Brenner B, Kalina U, Knaub S, Nagy A, Ostermann H. Pro-thrombin complex concentrate (Beriplex P/N) for emergency anticoagu-lation reversal: a prospective multinational clinical trial. J Thromb Haemost 2008;6:622-631.
71. Dowlatshahi D, Butcher KS, Asdaghi N, et al. Poor prognosis in warfarin-associated intracranial hemorrhage despite anticoagulation reversal. Stroke 2012;43:1812-1817.
72. Holland L, Warkentin TE, Crowther MA, Johnston MA, Sarode R. Sub-optimal effect of a three-factor prothrombin complex concentrate (profil-nin-SD) in correcting supratherapeutic international normalized ratio due to warfarin overdosage. Transfusion 2009;49:1171-1177.
73. Solbeck S, Ostrowski SR, Johansson PI. A review of the clinical utility of INR to monitor and guide administration of prothrombin complex concentrate to orally anticoagulated patients. Thromb J 2012;10:5.
74. Logan AC, Goodnough LT. Recombinant factor VIIa: an assessment of evidence regarding its efficacy and safety in the off-label setting. Hema-tology 2010;2010:153-159.
75. O'Connell KA, Wood JJ, Wise RP, Lozier JN, Braun MM. Thromboem-bolic adverse events after use of recombinant human coagulation factor VIIa. JAMA 2006;295:293-298.
76. Levi M, Levy JH, Andersen HF, Truloff D. Safety of recombinant activated factor VII in randomized clinical trials. N Engl J Med 2010; 363:1791-1800.
77. Ilyas C, Beyer GM, Dutton RP, Scalea TM, Hess JR. Recombinant factor VIIa for warfarin-associated intracranial bleeding. J Clin Anesth 2008;20: 276-279.
78. Dager WE, King JH, Regalia RC, et al. Reversal of elevated international normalized ratios and bleeding with low-dose recombinant activated factor VII in patients receiving warfarin. Pharmacotherapy 2006;26:1091-1098.
79. Roitberg B, Emechebe-Kennedy O, Amin-Hanjani S, Mucksavage J, Tesoro E. Human recombinant factor VII for emergency reversal of co-agulopathy in neurosurgical patients: a retrospective comparative study. Neurosurgery 2005;57:832-836.
80. Brody DL, Aiyagari V, Shackleford AM, Diringer MN. Use of recombi-nant factor VIIa in patients with warfarin-associated intracranial hemorrhage. Neurocrit Care 2005;2:263-267.
81. Freeman WD, Brott TG, Barrett KM, et al. Recombinant factor VIIa for rapid reversal of warfarin anticoagulation in acute intracranial hemorrhage. Mayo Clin Proc 2004;79:1495-1500.
82. Lin J, Hanigan WC, Tarantino M, Wang J. The use of recombinant activated factor VII to reverse warfarin-induced anticoagulation in patients with hemorrhages in the central nervous system: preliminary findings. J Neurosurg 2003;98:737-740.
83. Sorensen B, Johansen P, Nielsen GL, Sorensen JC, Ingerslev J. Reversal of the international normalized ratio with recombinant activated factor VII in central nervous system bleeding during warfarin thromboprophy-laxis: clinical and biochemical aspects. Blood Coagul Fibrinolysis 2003; 14:469-477.
84. Veshchev I, Elran H, Salame K. Recombinant coagulation factor VIIa for rapid preoperative correction of warfarin-related coagulopathy in patients with acute subdural hematoma. Med Sci Monit 2002;8:CS98-100.
85. Deveras RA, Kessler CM. Reversal of warfarin-induced excessive anti-coagulation with recombinant human factor VIIa concentrate. Ann Intern Med 2002;137:884-888.
86. Stangier J, Rathgen K, Stahle H, Mazur D. Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etex-ilate: an open-label, parallel-group, single-centre study. Clin Pharmacokinet 2010;49:259-268.
87. Wychowski MK, Kouides PA. Dabigatran-induced gastrointestinal bleeding in an elderly patient with moderate renal impairment. Ann Pharmacother. 2012;46:e10. doi: 10.1345/aph.1Q747.
88. Kaatz S, Kouides PA, Garcia DA, et al. Guidance on the emergent reversal of oral thrombin and factor Xa inhibitors. Am J Hematol 2012; 87:S141-145.
89. van Ryn J, Stangier J, Haertter S, et al. Dabigatran etexilate-a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost 2010;103: 1116-1127.
90. Eerenberg ES, Kamphuisen PW, Sijpkens MK, Meijers JC, Buller HR, Levi M. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation 2011;124:1573-1579.
91. Marlu R, Hodaj E, Paris A, et al. Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban: a randomised crossover ex-vivo study in healthy volunteers. Thromb Haemost 2012; 108:217-224.
92. Harinstein LM, Morgan JW, Russo N. Treatment of dabigatran-associat-ed bleeding: case report and review of the literature. J Pharm Pract 2012 Nov 16. [Epub ahead of print]
93. Harvey P. Risky anticoagulants: meds have the potential to turn minor trauma into a major disaster. JEMS 2012;37(8):30-31.
94. Chen BC, Viny AD, Garlich FM, et al. Hemorrhagic complications associated with dabigatran use. Clin Toxicol (Phila) 2012;50:854-857.
95. Dy EA, Shiltz DL. Hemopericardium and cardiac tamponade associated with dabigatran use. Ann Pharmacother 2012;46:e18. doi: 10.1345/aph.1R112.
96. Mastrobuoni S, Robblee JA, Boodhwani M. Spontaneous ascending aortic intramural haematoma in a patient on dabigatran. Interact Cardiovasc Thorac Surg 2012;15:299-300.
97. Kernan L, Ito S, Shirazi F, Boesen K. Fatal gastrointestinal hemorrhage after a single dose of dabigatran. Clin Toxicol (Phila) 2012;50:571-573.
98. Weitz JI, Quinlan DJ, Eikelboom JW. Periprocedural management and approach to bleeding in patients taking dabigatran. Circulation 2012; 126:2428-2432.
99. FDA approves Kcentra for the urgent reversal of anticoagulation in adults with major bleeding. www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm350026.htm (accessed 2013 Apr 30).
100. Study of OCTAPLEX and FFP in patients under Vit K therapy antagonist needing urgent surgery or invasive procedures. www.clinicaltrials.gov (accessed 2012 Oct 30).
101. Review of anticoagulation therapies in atrial fibrillation. Updated: 18 December 2012. Australian Government. Department of Health and Ageing. http://www.pbs.gov.au/info/publication/factsheets/shared/anticoagulation-review (accessed 2012 Oct 30).
102. Guideline for the management of bleeding on dabigatran (Pradaxa). Portland, ME: Maine Medical Center, Department of Emergency Medicine, February 9, 2012: 3. http://www.guideline.gov/content.aspx?id=36840&search=bleeding (accessed 2012 Dec 15).
103. National Institute for Health and Clinical Excellence (NICE). Acute upper gastrointestinal bleeding: management. Clinical guideline no. 141. London, England: National Institute for Health and Clinical Excellence, June 23, 2012.
104. Study to evaluate the safety, pharmacokinetics and pharmacodynamics of BI 655075 administered alone or with dabigatran etexilate. www. clinicaltrials.gov (accessed 2013 Feb 27).
105. Choi SH, Smith SA, Morrissey JH. Polyphosphate is a cofactor for the activation of factor XI by thrombin. Blood 2011;118:6963-6970.
106. Smith SA, Choi SH, Collins JN, Travers RJ, Cooley BC, Morrissey JH. Inhibition of polyphosphate as a novel strategy for preventing thrombosis and inflammation. Blood 2012;120:5103-5110.